

Poster presentation

Open Access

Risk Factors for CD4 Lymphopenia in Patients Treated With a Tenofovir/Didanosine High Dose-containing Highly Active Antiretroviral Therapy Regimen

Viviane Loungoussou* ‡

Address: L'Association Soliderite Sainte, Congo

Email: Viviane Loungoussou* - viviane_loungoussou@yahoo.fr

* Corresponding author ‡Presenting author

from 2005 International Meeting of The Institute of Human Virology
Baltimore, USA, 29 August – 2 September 2005

Published: 8 December 2005

Retrovirology 2005, **2**(Suppl 1):P61 doi:10.1186/1742-4690-2-S1-P61

In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed. Ninety-five HIV-positive patients were followed for 562 days, and 37 lost at least 50 CD4 cells, with a median delay of 274 days. Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg.